Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ono Pharmaceutical Co's other current liabilities for the quarter that ended in Mar. 2026 was 円31,449 Mil.
Ono Pharmaceutical Co's quarterly other current liabilities
increased
from Sep. 2025 (円22,833 Mil) to Dec. 2025 (円27,188 Mil) and
increased
from Dec. 2025 (円27,188 Mil) to Mar. 2026 (円31,449 Mil).
Ono Pharmaceutical Co's annual other current liabilities
increased
from Mar. 2024 (円18,530 Mil) to Mar. 2025 (円21,731 Mil) and
increased
from Mar. 2025 (円21,731 Mil) to Mar. 2026 (円31,449 Mil).
Ono Pharmaceutical Co Other Current Liabilities Related Terms
Ono Pharmaceutical Co Other Current Liabilities Historical Data
* Premium members only.
The historical data trend for Ono Pharmaceutical Co's Other Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co Other Current Liabilities Chart
Ono Pharmaceutical Co Other Current Liabilities Calculation
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of 円31,449 Mil mean?
Ono Pharmaceutical Co (TSE:4528) has a Other Current Liabilities of 円31,449 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ono Pharmaceutical Co.
Is Ono Pharmaceutical Co's Other Current Liabilities too high?
Ono Pharmaceutical Co's current Other Current Liabilities is 円31,449 Mil. Overall, Ono Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Other Current Liabilities compare to LLY and JNJ?
Ono Pharmaceutical Co's Other Current Liabilities of 円31,449 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ono Pharmaceutical Co. Ono Pharmaceutical Co's current Other Current Liabilities is 円31,449 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,229.53, compared to a current price of 円2,398.50 — trading 7.6% above its estimated fair value. The current Other Current Liabilities is 円31,449 Mil. Ono Pharmaceutical Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current Other Current Liabilities is 円31,449 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円2,398.50 is trading 7.6% above its estimated GF Value™ of 円2,229.53.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4528:
Other Current Liabilities: 円31,449 Mil
GF Value™: 円2,229.53 vs. price of 円2,398.50 (7.6% above fair value)
No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
89GF Score
Get the complete analysis for TSE:4528
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4528 has been successfully added to your 
